🔥🐔 BizChicken 🐔🔥

Companies Similar to Madrigal Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Rencofilstat

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drug therapies for chronic liver diseases, particularly through the development of Rencofilstat, a cyclophilin inhibitor aimed at treating non-alcoholic steatohepatitis (NASH) and reducing liver fibrosis and tumors.

Tags: NASH, Rencofilstat, biopharmaceutical, cyclophilin inhibitor, drug therapy, liver disease

Symbol: HEPA

Recent Price: $0.43

Industry: Biotechnology

CEO: Mr. John Patrick Brancaccio CPA

Sector: Healthcare

Employees: 22

Address: 399 Thornall Street, Edison, NJ 08837

Phone: 732 902 4000

Leadership

  • John P. Brancaccio, Interim Chief Executive Officer, Interim Chief Financial Officer, and Chairman of the Board

Last updated: 2024-12-31

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Highest

EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.

Tags: biotechnology, diseases, healthcare, injections, medicines, pharmaceuticals, treatment

Symbol: REGN

Recent Price: $702.59

Industry: Biotechnology

CEO: Dr. Leonard S. Schleifer M.D., Ph.D.

Sector: Healthcare

Employees: 14165

Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707

Phone: 914 847 7000

Leadership

  • Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
  • George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
  • Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
  • Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
  • Leonard Brooks, Senior Vice President, Treasurer
  • John Calabro, Senior Vice President, Internal Audit
  • Christina Chan, Senior Vice President, Corporate Affairs
  • Larry Coury, PhD, Senior Vice President, Associate General Counsel
  • Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
  • Matthew Everett, Senior Vice President, Global Procurement
  • Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
  • Rick Hall, Senior Vice President, Human Resources
  • Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
  • Nouhad Husseini, Senior Vice President, Business Development
  • Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
  • Melissa Lozner, Senior Vice President, Chief Compliance Officer
  • Marion McCourt, Executive Vice President, Commercial
  • Bob McCowan, Senior Vice President, IT and Chief Information Officer
  • Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
  • Richard O’Neal, Senior Vice President, Market Access
  • Sally A. Paull, Executive Vice President, Human Resources
  • Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
  • George Poth, Senior Vice President, Real Estate & Facilities Management
  • Alessandra Ravetti, Senior Vice President, Associate General Counsel
  • Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
  • David Snow, Senior Vice President, Global Head, Dupixent Franchise
  • Mark Volpe, Senior Vice President, Tax
  • Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
  • Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
  • Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
  • Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
  • Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
  • Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
  • Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
  • Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
  • Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
  • Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
  • Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
  • Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
  • Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
  • Christos Kyratsous, PhD, Senior Vice President, Research
  • Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
  • John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
  • Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
  • Lynn Macdonald, PhD, Senior Vice President, Research
  • Lori Morton, PhD, Senior Vice President, Research
  • Andrew Murphy, PhD, Executive Vice President, Research
  • Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
  • William Olson, PhD, Senior Vice President, Therapeutic Proteins
  • Mohammed Shameem, PhD, Senior Vice President, Formulations Development
  • L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
  • Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
  • Neil Stahl, PhD, Executive Vice President, Research and Development
  • Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
  • Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
  • Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
  • Frederick Austin, Senior Vice President, Quality Control, Raheen
  • Christine Childrose, Senior Vice President, Human Resources and HR Operations
  • David Crenshaw, Senior Vice President, Associate General Counsel
  • Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
  • Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
  • Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
  • Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
  • Scott Oberman, Senior Vice President, Supply Chain Operations
  • David Simon, Senior Vice President, IOPS Finance and Business Operations
  • Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
  • Benjamin Yocum, Senior Vice President, Manufacturing Operations
  • James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
  • Bonnie L. Bassler, PhD, Director
  • Michael S. Brown, MD, Director
  • N. Anthony Coles, MD, Chair of the Board
  • Joseph L. Goldstein, MD, Director
  • Kathryn Guarini, PhD, Director
  • Christine A. Poon, Lead Independent Director
  • Arthur F. Ryan, Director
  • Huda Y. Zoghbi, MD, Director
  • Samantha Dickon, Director, Development Program Management
  • Gervasio Batista, Sr. Scientist, Neuroscience
  • James K. Gibson, Senior Regional Director, Immunology/Pulmonary
  • Beth Brause, Director, Field Reimbursement Management
  • Eric Prendergast, Director, Pricing Strategy
  • Ashley Neff, Manager, Digital Communications
  • Shari Loock, Associate Director, Sourcing
  • Jennifer Davidson Hamilton, VP and Head of Precision Medicine
  • Yi Zhang, Director, Health Economics & Outcomes Research
  • Wilson Caldwell III, Director, GCO Vendor & Relationship Management
  • David Stein, Director, Medical Operations
  • Regeneron, Corporate
  • Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
  • Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
  • Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
  • Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
  • Jessie Brown, Manager, Integrative Translational Genetics
  • Gisu Eom, Lead Cloud DevOps Engineer
  • Carmen Kenworthy, Scientist, Velocigene
  • Ralph Hazlewood, Sr. Manager, Research Program Management
  • Brandy Bennett, Sr. Director, R&D Strategy & Operations

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Highest

Emverm, Rytary, Unithroid

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products across various dosage forms and therapeutic areas, operating through Generics, Specialty, and Av KARE segments.

Tags: Generics, Healthcare, Pharmaceuticals, Specialty, Therapeutics

Symbol: AMRX

Recent Price: $7.83

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Chirag K. Patel

Sector: Healthcare

Employees: 7850

Address: 400 Crossing Boulevard, Bridgewater, NJ 08807

Phone: 908 947 3120

Leadership

  • Chirag Patel, President and Co-Chief Executive Officer
  • Chintu Patel, Co-Chief Executive Officer
  • Tasos Konidaris, Executive Vice President, Chief Financial Officer
  • Nikita Shah, Executive Vice President, Chief Human Resources Officer
  • Jason B. Daly, Esq., Senior Vice President, Chief Legal Officer & Corporate Secretary
  • Gregory Sgammato, Senior Vice President, Corporate Development
  • Andrew S. Boyer, Executive Vice President, Chief Commercial Officer – Generics
  • Joe Renda, Senior Vice President, Chief Commercial Officer - Specialty
  • Shyamakant Giri, President, India Business & Emerging Markets
  • Sanjay Kumar Jain, PhD, Chief Quality Officer
  • Srinivas Kone, PhD, Senior Vice President, Chief Scientific Officer – Generics
  • Richard D’Souza, PhD, Senior Vice President, Specialty R&D
  • Maryll W. Toufanian, Senior Vice President, Regulatory Strategy and Government Affairs
  • Pranav Mehta, Senior Vice President, Strategic Sourcing & Supply Management
  • Sandeep R. Raktate, President, Operations – India & Ireland

Last updated: 2024-12-31

Altimmune, Inc.

Altimmune, Inc. logo
Market Cap: Medium
Employees: Lowest

Pemvidutide

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases with lead product candidate pemvidutide, and Hep Tcell in clinical trials.

Tags: Phase 1b trial, Phase 2 trial, biopharmaceutical, hepatic, liver diseases, obesity

Symbol: ALT

Recent Price: $7.32

Industry: Biotechnology

CEO: Dr. Vipin K. Garg Ph.D.

Sector: Healthcare

Employees: 59

Address: 910 Clopper Road, Gaithersburg, MD 20878

Phone: 240 654 1450

Last updated: 2024-12-31

89bio, Inc.

89bio, Inc. logo
Market Cap: Medium
Employees: Low

pegozafermin

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardio-metabolic diseases, primarily through its lead product candidate, pegozafermin, designed to treat nonalcoholic steatohepatitis and severe hypertriglyceridemia.

Tags: biopharmaceutical, cardio-metabolic, clinical-stage, hypertriglyceridemia, liver diseases, nonalcoholic steatohepatitis, pegozafermin

Symbol: ETNB

Recent Price: $7.87

Industry: Biotechnology

CEO: Mr. Rohan Palekar

Sector: Healthcare

Employees: 70

Address: 142 Sansome Street, San Francisco, CA 94104

Phone: 415 432 9270

Last updated: 2024-12-31

CervoMed Inc.

CervoMed Inc. logo
Market Cap: Low
Employees: Lowest

neflamapimod

Cervo Med Inc. is a clinical-stage biotechnology company focused on developing and commercializing drug treatments for neurodegenerative diseases, including neflamapimod for conditions like dementia with Lewy bodies, Alzheimer's diseases, and brain stroke recovery.

Tags: Alzheimer's, biotechnology, brain stroke recovery, dementia, drug development, neurodegenerative diseases

Symbol: CRVO

Recent Price: $2.39

Industry: Biotechnology

CEO: Dr. John J. Alam M.D.

Sector: Healthcare

Employees: 8

Address: 20 Park Plaza, Boston, MA 02116

Phone: 617-744-4400

Last updated: 2024-12-31

Geron Corporation

Geron Corporation logo
Market Cap: High
Employees: Low

Imetelstat

Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapeutics for myeloid hematologic malignancies, notably through their telomerase inhibitor, imetelstat, which is in Phase 3 clinical trials.

Tags: biopharmaceutical, clinical trials, imetelstat, myeloid hematologic malignancies, telomerase inhibitor

Symbol: GERN

Recent Price: $3.40

Industry: Biotechnology

CEO: Dr. John A. Scarlett M.D.

Sector: Healthcare

Employees: 141

Address: 919 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 473 7700

Leadership

  • John A. Scarlett, M.D., Chairman of the Board, President and Chief Executive Officer
  • Melissa A. Kelly Behrs, Executive Vice President, Business Operations and Chief Alliance Officer
  • Faye Feller, M.D., Executive Vice President, Chief Medical Officer
  • Andrew J. Grethlein, Ph.D., Executive Vice President, Chief Operating Officer
  • Edward Koval, Executive Vice President and Chief Business Officer
  • Shannon T. Odam, Senior Vice President, Chief People Officer
  • Michelle Robertson, Executive Vice President, Chief Financial Officer and Treasurer
  • Scott A. Samuels, Esq., Executive Vice President, Chief Legal Officer and Secretary
  • Jim Ziegler, Executive Vice President, Chief Commercial Officer
  • Gaurav Aggarwal, M.D., Compensation Committee, Strategic Committee (Chair)
  • Dawn C. Bir, Nominating and Corporate Governance Committee (Chair), Compensation Committee
  • V. Bryan Lawlis, Ph.D., Audit Committee, Nominating and Corporate Governance Committee
  • John F. McDonald, Audit Committee, Strategic Committee
  • Susan M. Molineaux, Ph.D., Compensation Committee (Chair), Nominating and Corporate Governance Committee
  • Elizabeth G. O’Farrell, Lead Director, Audit Committee (Chair), Strategic Committee
  • Robert J. Spiegel, M.D., FACP, Compensation Committee, Nominating and Corporate Governance Committee

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

MEI Pharma, Inc.

MEI Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

Zandelisib

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing and commercializing therapies for cancer treatment, including Zandelisib and Voruciclib.

Tags: Voruciclib, Zandelisib, cancer therapy, clinical trials, oncology, pharmaceutical

Symbol: MEIP

Recent Price: $2.45

Industry: Biotechnology

CEO: Mr. Justin J. File

Sector: Healthcare

Employees: 28

Address: 11455 El Camino Real, San Diego, CA 92130

Phone: 858 369 7100

Last updated: 2024-12-31

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

LIVMARLI

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases, with products like LIVMARLI and Volixibat.

Tags: LIVMARLI, Volixibat, biopharmaceutical, orphan diseases, rare diseases

Symbol: MIRM

Recent Price: $41.18

Industry: Biotechnology

CEO: Mr. Christopher Peetz

Sector: Healthcare

Employees: 294

Address: 950 Tower Lane, Foster City, CA 94404

Phone: 650 667 4085

Leadership

  • Chris Peetz, Chief Executive Officer, Mirum Pharmaceuticals
  • Erin Campany, Senior Vice President, Human Resources
  • Eric Bjerkholt, Chief Financial Officer
  • Jean-Luc Girardet, Ph.D., Senior Vice President, Technical Operations
  • Vinita Kumar, Senior Vice President, Quality
  • Lara Longpre, Chief Development Officer
  • Joanne Quan, M.D., Chief Medical Officer
  • Peter Radovich, President & Chief Operating Officer
  • Paul Ross, Chief Compliance Officer
  • Pamela Vig, Ph.D., Chief Scientific Officer and Head of Research
  • Laura Brege, Board Member
  • Patrick Heron, Managing General Partner, Frazier Healthcare Partners
  • Tim Walbert, Former Chairman, President and Chief Executive Officer, Horizon Therapeutics; Sr. Advisor, Amgen
  • Lon Cardon, Ph.D., FMedSci., Board Member
  • William C. Fairey, Board Member
  • Laurent Fischer, M.D., President & Chief Executive Officer, Adverum Biotechnologies
  • Mike Grey, Chairman of the Board, Mirum Pharmaceuticals
  • Saira Ramasastry, MS, MPhil, Managing Partner, Life Sciences Advisory, LLC

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

Tavalisse

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Tags: biotechnology, cancer, drug development, hematologic disorders, immune diseases

Symbol: RIGL

Recent Price: $16.47

Industry: Biotechnology

CEO: Mr. Raul R. Rodriguez

Sector: Healthcare

Employees: 147

Address: 1180 Veterans Boulevard, South San Francisco, CA 94080

Phone: 650 624 1100

Last updated: 2024-12-31

Rezolute, Inc.

Rezolute, Inc. logo
Market Cap: Low
Employees: Lowest

RZ358

Rezolute, Inc. is a clinical stage biopharmaceutical company focused on developing transformative therapies for metabolic diseases related to chronic glucose imbalance. Its lead product, RZ358, is aimed at treating congenital hyperinsulinism.

Tags: biopharmaceutical, clinical stage, congenital hyperinsulinism, genetic disorder, glucose imbalance, metabolic diseases

Symbol: RZLT

Recent Price: $4.89

Industry: Biotechnology

CEO: Mr. Nevan Charles Elam J.D.

Sector: Healthcare

Employees: 59

Address: 201 Redwood Shores Parkway, Redwood City, CA 94065

Phone: 650 206 4507

Last updated: 2024-12-31

Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Medium

G-MAB antibody library, Sofusa drug delivery technology, ZTlido

Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focusing on developing therapies for various diseases, including cancer and autoimmune diseases, using innovative antibody libraries and drug delivery systems.

Tags: CAR-T therapy, antibody library, autoimmune diseases, biopharmaceutical, cancer therapy, drug delivery

Symbol: SRNE

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Henry H. Ji Ph.D.

Sector: Healthcare

Employees: 949

Address: 4955 Directors Place, San Diego, CA 92121

Phone: 858 203 4100

Last updated: 2024-12-31

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Tamibarotene

Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer treatment, gene control, myelodysplastic syndrome, pharmaceutical development

Symbol: SYRS

Recent Price: $0.25

Industry: Biotechnology

CEO: Mr. Conley Chee

Sector: Healthcare

Employees: 68

Address: 35 CambridgePark Drive, Cambridge, MA 02140

Phone: 617 744 1340

Leadership

  • Conley Chee, President and Chief Executive Officer
  • Jason Haas, Chief Financial Officer
  • Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
  • Lisa Roberts, VP Human Resources
  • David A. Roth, M.D., Chief Medical Officer
  • Kristin Stephens, Chief Development Officer

Last updated: 2024-12-31

BioCardia, Inc.

BioCardia, Inc. logo
Market Cap: Lowest
Employees: Lowest

Cardi AMP Cell Therapy System

Bio Cardia, Inc. is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Their lead candidate, the Cardi AMP Cell Therapy System, targets heart failure and myocardial ischemia, with additional developments in cell delivery and therapeutic platforms.

Tags: cardiovascular, cell therapy, clinical-stage, pulmonary diseases, regenerative medicine

Symbol: BCDA

Recent Price: $2.15

Industry: Biotechnology

CEO: Dr. Peter A. Altman Ph.D.

Sector: Healthcare

Employees: 16

Address: 320 Soquel Way, Sunnyvale, CA 94085

Phone: 650 226 0120

Leadership

  • David McClung, CFO
  • Edward Gillis, Sr. VP of Devices
  • Debby Holmes-Higgin, MPH, VP of Clinical
  • Andrew Scott Blank, Chairman
  • Simon H. Stertzer, M.D., Professor of Medicine, Emeritus
  • Jay M. Moyes, Director
  • Bill Facteau, President and Chief Executive Officer
  • Richard Krasno, Ph.D., Director
  • Jim Allen, Chief Executive Officer and President
  • Peter Altman, Ph.D., President and Chief Executive Officer

Last updated: 2024-12-31

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

resmetirom

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focusing on developing and commercializing therapeutic candidates for cardiovascular, metabolic, and liver diseases, with its lead product candidate resmetirom targeting non-alcoholic steatohepatitis.

Tags: biopharmaceutical, cardiovascular, clinical-stage, liver diseases, metabolic, non-alcoholic steatohepatitis, resmetirom, therapeutic candidates

Symbol: MDGL

Recent Price: $311.62

Industry: Biotechnology

CEO: Mr. William J. Sibold

Sector: Healthcare

Employees: 376

Address: Four Tower Bridge, West Conshohocken, PA 19428

Phone: 267 824 2827

Leadership

  • BILL SIBOLD, Chief Executive Officer
  • REBECCA TAUB, M.D., Director, Founder, Chief Medical Officer and President of Research & Development
  • MARDI C. DIER, Chief Financial Officer
  • CAROLE HUNTSMAN, Chief Commercial Officer
  • CLINT WALLACE, Chief Human Resources Officer
  • RONALD FILIPPO, Chief Information Officer
  • STEPHEN DODGE, PHARM D, M.B.A., Senior Vice President, Global Medical Affairs
  • SHANNON KELLEY, General Counsel
  • MARK BARRETT, Chief Business Officer
  • MARK UNDERWOOD, Senior Vice President, Business Planning & Operations
  • Julian C. Baker, Chairman and Director
  • Kenneth M. Bate, Director
  • Raymond Cheong, M.D., Ph.D., Director
  • Fred Craves, Ph.D., Director
  • James M. Daly, Director
  • Paul A. Friedman, M.D., Director
  • Richard S. Levy, M.D., Director
  • Bill Sibold, Director, Chief Executive Officer
  • Rebecca Taub, M.D., Director, Founder, Chief Medical Officer and President of Research & Development

Last updated: 2024-12-31

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Esmethadone (d-methadone, dextromethadone, REL-1017)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing products for central nervous system (CNS) diseases. Their lead product, Esmethadone, is in Phase 3 clinical trials for treating major depressive disorder.

Tags: CNS disorders, Esmethadone, biotechnology, clinical-stage, major depressive disorder

Symbol: RLMD

Recent Price: $0.46

Industry: Biotechnology

CEO: Dr. Sergio Traversa M.B.A., Pharm.D.

Sector: Healthcare

Employees: 20

Address: 2222 Ponce de Leon Boulevard, Coral Gables, FL 33134

Phone: 786 629 1376

Last updated: 2024-12-31